Valuation: Celsion Corporation

Market Cap 6.85M 5.93M 5.54M 5.07M 9.55M 653M 9.69M 64.99M 25.5M 327M 25.72M 25.16M 1.09B P/E 2026 *
-0.48x
P/E 2027 * -0.72x
Enterprise Value 6.85M 5.93M 5.54M 5.07M 9.55M 653M 9.69M 64.99M 25.5M 327M 25.72M 25.16M 1.09B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Change 5-day change 1-year change 3-year change Capi.($)
-0.70%+24.68%+76.72%+103.05% 70.85B
-2.35%+2.88%+35.39%+64.72% 55.41B
-0.37%+36.09%+19.04%+499.13% 29.43B
-0.30%+18.51%+56.61%+4.86% 24.12B
-0.56%+0.84%-15.69%-13.85% 23.31B
+0.05%+6.12%+46.81%-21.81% 18.37B
+9.77%+25.32%+252.40%+442.16% 16.99B
0.00%+10.84%+31.14%+628.97% 16.1B
-1.43%-6.46%+40.02%+143.40% 13.12B
Average +0.46%+390.71%+60.27%+205.63% 29.75B
Weighted average by Cap. -0.23%+349.16%+56.52%+166.19%

Financials

2026 *2027 *
Net sales - -
Net income -16.41M -14.2M -13.28M -12.13M -22.87M -1.56B -23.22M -156M -61.09M -783M -61.61M -60.27M -2.61B -23.33M -20.19M -18.88M -17.25M -32.51M -2.22B -33.02M -221M -86.86M -1.11B -87.59M -85.68M -3.71B
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-